Aurora Cannabis (ACB): Prepare for More Dilution Yet Again, , on October 29, 2020 at 3:28 am

Financial News
By High West Capital Partners
On October 29, 2020
In Financial News
Tags:

More dilution could be on the way for beleaguered shareholders of Aurora Cannabis (ACB). The company gave note of a preliminary prospectus, which over the next 25 months authorizes the Canadian cannabis player to issue up to US$500 million in securities. The prospectus also noted exhaustion of the company’s ATM, through which it has raised gross proceeds of US$214.7 million since its fiscal fourth quarter.Aurora might have all sorts of issues, but it is an expert at issuing shares. Over the past 6 years, the share count has increased by almost 9,250%.Jefferies analyst Owen Bennett is not surprised by the latest attempt to pad the coffers, having already argued post Aurora’s September business update and then again following the company’s F4Q results, that in order to support near-term operations and debt obligations, Aurora would exhaust its ATM and require further raises.However, the analyst is taken back by one aspect of the raise.“What is surprising is the size of the possible raise and the dilution that comes with this. Exhaustion of the ATM would have already represented c26% dilution, while full use of the US$500mn would be an additional c50% based on the current share price,” the analyst noted.That said, Bennett does count several positives the unwelcome surprise offers.“First,” he says, “The news is now out of the way, and by announcing such a large number there is unlikely to be any more surprises.”Secondly, while Aurora is expected to turn EBITDA positive this year, Bennett notes that without an additional raise it was “at risk of under investing in the business.” The money should go toward supporting its top line in Canada, where Aurora still “has a very strong brand and product portfolio,” while its European and, particularly, German investments could get an injection, too.Lastly, and most importantly, with potential federal legislation looming across the border, the money could be well spent in the U.S.“It needs to establish a strong CBD business (and US infrastructure) ahead of this, and then be prepared to invest in cannabis if any laws change,” Bennett opined. “With most institutional money likely to be focused on US names should we see legalisation, if Canadian names can’t argue a strong case for competitiveness, they may struggle to catch a bid.”Overall, there’s no change to Bennett’s rating which stays a Hold, while the C$6.90 (US$5.24) price target suggests possible upside of 24%. (To watch Bennett’s track record, click here)Barring 1 Buy rating, all 13 other analysts to have posted an Aurora review over the past 3 months are on the same page as Bennett and also say Hold. However, they might as well have said Buy as the C$9.30 (US$6.99) average price target implies upside of 83% over the next 12 months. (See ACB stock analysis on TipRanks)To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.,

Aurora Cannabis (ACB): Prepare for More Dilution Yet AgainMore dilution could be on the way for beleaguered shareholders of Aurora Cannabis (ACB). The company gave note of a preliminary prospectus, which over the next 25 months authorizes the Canadian cannabis player to issue up to US$500 million in securities. The prospectus also noted exhaustion of the company’s ATM, through which it has raised gross proceeds of US$214.7 million since its fiscal fourth quarter.Aurora might have all sorts of issues, but it is an expert at issuing shares. Over the past 6 years, the share count has increased by almost 9,250%.Jefferies analyst Owen Bennett is not surprised by the latest attempt to pad the coffers, having already argued post Aurora’s September business update and then again following the company’s F4Q results, that in order to support near-term operations and debt obligations, Aurora would exhaust its ATM and require further raises.However, the analyst is taken back by one aspect of the raise.“What is surprising is the size of the possible raise and the dilution that comes with this. Exhaustion of the ATM would have already represented c26% dilution, while full use of the US$500mn would be an additional c50% based on the current share price,” the analyst noted.That said, Bennett does count several positives the unwelcome surprise offers.“First,” he says, “The news is now out of the way, and by announcing such a large number there is unlikely to be any more surprises.”Secondly, while Aurora is expected to turn EBITDA positive this year, Bennett notes that without an additional raise it was “at risk of under investing in the business.” The money should go toward supporting its top line in Canada, where Aurora still “has a very strong brand and product portfolio,” while its European and, particularly, German investments could get an injection, too.Lastly, and most importantly, with potential federal legislation looming across the border, the money could be well spent in the U.S.“It needs to establish a strong CBD business (and US infrastructure) ahead of this, and then be prepared to invest in cannabis if any laws change,” Bennett opined. “With most institutional money likely to be focused on US names should we see legalisation, if Canadian names can’t argue a strong case for competitiveness, they may struggle to catch a bid.”Overall, there’s no change to Bennett’s rating which stays a Hold, while the C$6.90 (US$5.24) price target suggests possible upside of 24%. (To watch Bennett’s track record, click here)Barring 1 Buy rating, all 13 other analysts to have posted an Aurora review over the past 3 months are on the same page as Bennett and also say Hold. However, they might as well have said Buy as the C$9.30 (US$6.99) average price target implies upside of 83% over the next 12 months. (See ACB stock analysis on TipRanks)To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage